Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 2Withdrawn 1Terminated 1Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Burkitt Lymphoma 6Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia, Biphenotypic, Acute 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Down Syndrome 1Blastic Plasmacytoid Dendritic Cell Neoplasm 1

Interventions

Cyclophosphamide 11venetoclax 10Dexamethasone 8Cytarabine 7Vincristine 5Azacitidine 4mogamulizumab 3fludarabine phosphate 3fludarabine 3daratumumab 3Specimen Handling 3Prednisone 3Methotrexate 3Doxorubicin 3Dasatinib 3Biopsy 3ruxolitinib 2prednylidene 2pegaspargase 2nelarabine 2deltacortene 2calaspargase pegol 2Rituximab 2Mercaptopurine 2Etoposide 2Decitabine 2Daunorubicin 2Calcium Dobesilate 2Bortezomib 2Asparaginase 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Precursor T-Cell Lymphoblastic Leukemia-Lymphoma × azathiopurine × Clear all
NCT00501826 2026-01-07

Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

M.D. Anderson Cancer Center

Phase 2 Recruiting
160 enrolled
LymphoidOther hematologic neoplasm

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡